Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Publications
PDF

Zeleris_Poster-1.pdf

Open PDF

Summary

In field conditions, Zeleris® achieved significant better performances than Nuflor®300 for the control of fever (until 48h after treatment) and for the clinical recovery (until 72h after treatment). These results are in line with current recommendation to take in consideration inflammation for the treatment of BRD.

Share this publication:

Publication file:

Download publication
This site is registered on wpml.org as a development site.